← Back to all trials
Recruiting
NCT07629544
A Study of DA-302168S in Participants With Overweight/Obesity
Conditions: Overweight and Obesity
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 840
Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD.
Location: Peking University People's Hospital Beijing
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.
Eligibility Criteria
Key Inclusion Criteria:
1. Age 18-75 years (inclusive), both males and females;
2. BMI requirements at screening: for obese participants, BMI ≥28 kg/m² with or without comorbidities; or for overweight participants, BMI ≥24.0 kg/m² and \
Source: ClinicalTrials.gov (NCT07629544). StuddyBuddy aggregates publicly available trial information.
